NeoPredics AG

🌟 𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐍𝐞𝐰𝐬 𝐟𝐫𝐨𝐦 𝐍𝐞𝐨𝐏𝐫𝐞𝐝𝐢𝐜𝐬! 🌟 We are thrilled to welcome 𝐏𝐫𝐨𝐟. Stefan Verlohren as the new 𝐂𝐡𝐚𝐢𝐫𝐦𝐚𝐧 𝐨𝐟 𝐨𝐮𝐫 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐚𝐧𝐝 𝐒𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜 𝐀𝐝𝐯𝐢𝐬𝐨𝐫𝐲 𝐁𝐨𝐚𝐫𝐝, effective January 1, 2025. With his expertise in maternal-fetal medicine, we’re poised to make even greater strides in advancing healthcare for women and newborns. Catch all the details in our press release here: #MaternalHealth #NeonatalCare #Innovation #HealthcareLeadership

Have you seen our presentation highlighting the 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀 we’re making in 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗶𝗻𝗴 𝗮 𝗽𝗿𝗲𝗲𝗰𝗹𝗮𝗺𝗽𝘀𝗶𝗮 𝗽𝗿𝗲𝗱𝗶𝗰𝘁𝗶𝗼𝗻 𝘁𝗼𝗼𝗹? Take a closer look at the poster below for insights into how we’re advancing maternal health care. If you’d like to learn more, don’t hesitate to reach out - we’d love to connect! #preeclampsia #predictiveanalytics

𝗗𝗶𝗱 𝗬𝗼𝘂 𝗞𝗻𝗼𝘄? In 2025, the NeoPredics team will be diligently working to bring our 𝗽𝗿𝗲𝗲𝗰𝗹𝗮𝗺𝗽𝘀𝗶𝗮 𝗽𝗿𝗲𝗱𝗶𝗰𝘁𝗶𝗼𝗻 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻 to market - a groundbreaking tool designed to help clinicians identify at-risk mothers earlier and improve outcomes for families. With maternal mortality rates projected to remain alarmingly high, our mission has never been more urgent. We’re committed to turning innovation into life-saving solutions that make a real impact in 2025 and beyond. Together, let’s create a future where every mother and baby has the best possible start in life. 

𝗦𝗲𝗮𝘀𝗼𝗻’𝘀 𝗚𝗿𝗲𝗲𝘁𝗶𝗻𝗴𝘀 𝗳𝗿𝗼𝗺 𝗡𝗲𝗼𝗣𝗿𝗲𝗱𝗶𝗰𝘀! 🎄 This holiday season, we reflect on the progress we’ve made and the meaningful work ahead. At NeoPredics, we’re committed to creating a brighter future for mothers and newborns through innovation in maternal and neonatal care. To our partners, supporters, and the incredible healthcare community, thank you for joining us on this journey to improve outcomes and save lives. Wishing you all a joyful holiday filled with warmth, love, and cherished moments.

We’re excited to share that Todd Usen has been appointed as 𝗖𝗵𝗮𝗶𝗿𝗺𝗮𝗻 𝗼𝗳 𝘁𝗵𝗲 𝗕𝗼𝗮𝗿𝗱  at NeoPredics AG. His leadership in MedTech and dedication to advancing women’s health will help guide us into an impactful future. Welcome to the NeoPredics family, Todd! #medtech #neopredics #board  Learn more about this exciting announcement here:

NeoPredics AG is on a mission to make sure that every baby has the best possible start to their life. They combine biological, physiological, and pharmacological data with a mathematical model to anticipate and mitigate the risk of jaundice in newborns. Today, 6 out of 10 babies develop jaundice. By identifying the risk of newborn diseases early, clinicians can make more informed care decisions for the millions of babies born each year. NeoPredics is utilizing digital health solutions and intelligent algorithms to support maternal, neonatal, and perinatal care. The company's prediction software will support clinical decision-makers, allowing them to personalize and optimize patient care based on deep medical data and science. The company has achieved many major milestones recently including: • Secured a strategic investment from Springhood Ventures, enabling the company to accelerate the development of its AI-powered healthcare solutions. • Announced a commercial collaboration with Dräger Medical, a global leader in medical technology, to enhance the implementation of its neonatal jaundice prediction tools in clinical settings. • Partnered with the Charité in Germany, one of Europe’s top research hospitals, to advance its preeclampsia prediction technology and improve maternal care. • Achieved ISO 13485 certification underscoring NeoPredics’ dedication to developing safe, high-quality medical devices for global markets. • Received CE MDR certification, marking a significant step toward expanding its solutions across the European Union. We’re excited to announce that Thorsten Waloschek has been selected to present NeoPredics at LSI USA ‘25 March 17-21, 2025. Join us in Dana Point to meet with Thorsten and learn more about NeoPredics.

𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗡𝗲𝗼𝗻𝗮𝘁𝗮𝗹 𝗖𝗮𝗿𝗲: 𝗥𝗲𝘀𝘂𝗹𝘁𝘀 𝗳𝗿𝗼𝗺 𝗨𝗽𝗱𝗮𝘁𝗲𝗱 𝗝𝗮𝘂𝗻𝗱𝗶𝗰𝗲 𝗚𝘂𝗶𝗱𝗲𝗹𝗶𝗻𝗲𝘀 We wanted to share a recent article from Pediatrics, titled “𝗕𝗶𝗹𝗶𝗿𝘂𝗯𝗶𝗻 𝗠𝗲𝗮𝘀𝘂𝗿𝗲𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝗣𝗵𝗼𝘁𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗨𝘀𝗲 𝗔𝗳𝘁𝗲𝗿 𝘁𝗵𝗲 𝗔𝗔𝗣 𝟮𝟬𝟮𝟮 𝗡𝗲𝘄𝗯𝗼𝗿𝗻 𝗛𝘆𝗽𝗲𝗿𝗯𝗶𝗹𝗶𝗿𝘂𝗯𝗶𝗻𝗲𝗺𝗶𝗮 𝗚𝘂𝗶𝗱𝗲𝗹𝗶𝗻𝗲,” which highlights the impact of updated jaundice management practices. These findings show promising improvements in newborn care. 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗦𝘁𝘂𝗱𝘆: - 47% reduction in phototherapy use - 23% decrease in bilirubin measurements - No increase in readmissions or length of stay While these results are encouraging, gaps in consistent implementation remain. The BiliPredics jaundice management tool addresses these challenges by providing predictive analytics and decision-support tools to standardize care, reduce complications, and ensure better outcomes for newborns. 𝗢𝘂𝗿 𝗧𝗮𝗸𝗲𝗮𝘄𝗮𝘆: Guidelines, combined with innovative tools like BiliPredics, have the power to transform neonatal care. At NeoPredics, we’re committed to supporting clinicians with solutions that make a difference. https://lnkd.in/evHKQbQb We’d love to hear your thoughts on this topic. Share your insights in the comments below. #NeonatalCare #JaundiceManagement #InnovationInHealthcare #NeoPredics

𝗣𝗿𝗲𝗲𝗰𝗹𝗮𝗺𝗽𝘀𝗶𝗮 𝗶𝘀 𝗮 𝗹𝗶𝗳𝗲-𝘁𝗵𝗿𝗲𝗮𝘁𝗲𝗻𝗶𝗻𝗴 𝗰𝗼𝗺𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗽𝗿𝗲𝗴𝗻𝗮𝗻𝗰𝘆, 𝘁𝗮𝗸𝗶𝗻𝗴 𝘁𝗵𝗲 𝗹𝗶𝘃𝗲𝘀 𝗼𝗳 𝗰𝗼𝘂𝗻𝘁𝗹𝗲𝘀𝘀 𝗺𝗼𝘁𝗵𝗲𝗿𝘀 𝗮𝗻𝗱 𝗯𝗮𝗯𝗶𝗲𝘀 𝗲𝗮𝗰𝗵 𝘆𝗲𝗮𝗿. See the video below to discover how NeoPredics is addressing these heartbreaking statistics and working to safeguard women and children worldwide with our novel 3-component solution—because “we didn’t know” is no longer an option. #preeclampsia

Ready to pitch #NeoPredics at the Women‘s Health session during #healthtechforward in Barcelona. Let’s talk about #predictiveanalytics in #maternal and #neonatal care.

From #NeoPrediX to #NeoPredics. Our exciting journey continues and there are more great news on the horizon. Stay tuned!